IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.

<h4>Background</h4>To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIF...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vijayaprakash Suppiah, Silvana Gaudieri, Nicola J Armstrong, Kate S O'Connor, Thomas Berg, Martin Weltman, Maria Lorena Abate, Ulrich Spengler, Margaret Bassendine, Gregory J Dore, William L Irving, Elizabeth Powell, Margaret Hellard, Stephen Riordan, Gail Matthews, David Sheridan, Jacob Nattermann, Antonina Smedile, Tobias Müller, Emma Hammond, David Dunn, Francesco Negro, Pierre-Yves Bochud, Simon Mallal, Golo Ahlenstiel, Graeme J Stewart, Jacob George, David R Booth, International Hepatitis C Genetics Consortium (IHCGC)
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/35e1fae1f2ff4e0fbdcb58e851dcbeeb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.

Ejemplares similares